Growth Hormone Improves Social Impairments From Autism Linked Disorder
New research has found that a growth hormone can significantly improve the social impairment associated with autism spectrum disorder (ASD) in patients with a related genetic syndrome. The pilot study, conducted at the Icahn School of Medicine at Mount Sinai, focused on the use of insulin-like growth factor-1 (IGF-1) to treat Phelan-McDermid syndrome (PMS), a disorder caused by a deletion or mutation of the SHANK3 gene on chromosome 22. “Ours is the first controlled trial of any treatment for Phelan-McDermid syndrome,” said Alexander Kolevzon, MD, clinical director of the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai.
- Dr. Alexander Kolevzon, Associate Professor, Psychiatry, Pediatrics, Clinical Director, the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai
Additional Coverage:
Business Standard
News-Medical
Medical Xpress
Zee News
Eva A. Mistry, MBBS, MSCI, FAHA, Appointed Mount Sinai Health System Chair of Neurology
Sep 09, 2026 View All Press Releases
Mount Sinai Returns as Official Health Care Partner of the US Open Tennis Championships
Aug 20, 2026 View All Press Releases
The Mount Sinai Hospital Ranked Among Top in the Nation by U.S. News & World Report®
Aug 04, 2026 View All Press Releases
Loss of Radiation Therapy Clinics Could Widen Cancer Care Gaps Across the United States
Jul 10, 2026 View All Press Releases
